SCHEMBL5458312

SCHEMBL5458312

CC1(NC(=S)Nc2sc3c(c2C(N)=O)CCOC3)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 1/20 0.57
RAB7A P51149 1/20 0.50
PTPRC P08575 1/20 0.49
PTPN2 P17706 1/20 0.49
PTPN1 P18031 1/20 0.49
PTPRB P23467 1/20 0.49
PTPRE P23469 1/20 0.49
CXCR2 P25025 6/20 0.48
CNR2 P34972 2/20 0.47
ALDH1A1 P00352 6/20 0.47
MAPT P10636 5/20 0.47
NPC1 O15118 4/20 0.47
RAB9A P51151 4/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
KMT2A Q03164 3/20 0.47
HPGD P15428 2/20 0.47
LMNA P02545 2/20 0.47
NPSR1 Q6W5P4 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
MEN1 O00255 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5456256 0.83 CFTR (0.61) CFTRRAB7APTPRCPTPN2PTPN1
SCHEMBL5467477 0.82 CFTR (0.60) CFTRPTPRCPTPN2PTPN1PTPRB
SCHEMBL5455938 0.81 CNR2 (0.69) CFTRPTPRCPTPN2PTPN1PTPRB
SCHEMBL5448254 0.81 CFTR (0.55) CFTRRAB7APTPRCPTPN2PTPN1
SCHEMBL8290653 0.80 CFTR (0.67) CFTRPTPRCPTPN2PTPN1PTPRB
SCHEMBL5449075 0.80 CFTR (0.66) CFTRRAB7APTPRCPTPN2PTPN1
SCHEMBL5456413 0.79 CFTR (0.59) CFTRPTPRCPTPN2PTPN1PTPRB
SCHEMBL5445117 0.78 PTPRC (0.65) CFTRRAB7APTPRCPTPN2PTPN1
SCHEMBL5457480 0.77 CNR2 (0.61) CFTRPTPRCPTPN2PTPN1PTPRB
SCHEMBL5467520 0.77 ANO1 (0.67) CFTRPTPRCPTPN2PTPN1PTPRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 CFTR 2030/4885RAB7A 984/4885PTPRC 1457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.